Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

tandem diabetes care inc - TNDM

TNDM

Close Chg Chg %
30.15 0.59 1.94%

Open Market

30.74

+0.59 (1.94%)

Volume: 1.66M

Last Updated:

Nov 21, 2024, 3:58 PM EDT

Trade Now

Company Overview: tandem diabetes care inc - TNDM

TNDM Key Data

Open

$30.71

 Day Range

30.34 - 32.38

52 Week Range

17.87 - 53.69

 Market Cap

$1.98B

Shares Outstanding

65.68M

 Public Float

65.16M

Beta

1.37

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.94

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.64M

  

TNDM Performance

1 Week
 
 10.28%
 
1 Month
 
 -3.83%
 
3 Months
 
 -32.40%
 
1 Year
 
 58.27%
 
5 Years
 
 -55.94%
 

TNDM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 23
Full Ratings ➔

About tandem diabetes care inc - TNDM

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

TNDM At a Glance

Tandem Diabetes Care, Inc.
12400 High Bluff Drive
San Diego, California 92130
Phone 1-858-366-6900 Revenue 747.72M
Industry Medical Specialties Net Income -222,611,000.00
Sector Health Technology Employees 2,400
Fiscal Year-end 12 / 2024
View SEC Filings

TNDM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.57
Price to Book Ratio 6.182
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.473
Enterprise Value to Sales 2.50
Total Debt to Enterprise Value 0.222

TNDM Efficiency

Revenue/Employee 311,549.167
Income Per Employee -92,754.583
Receivables Turnover 7.084
Total Asset Turnover 0.746

TNDM Liquidity

Current Ratio 3.831
Quick Ratio 3.022
Cash Ratio 2.396

TNDM Profitability

Gross Margin 47.327
Operating Margin -20.66
Pretax Margin -29.457
Net Margin -29.772
Return on Assets -22.201
Return on Equity -59.081
Return on Total Capital -30.524
Return on Invested Capital -28.559

TNDM Capital Structure

Total Debt to Total Equity 132.533
Total Debt to Total Capital 56.995
Total Debt to Total Assets 43.632
Long-Term Debt to Equity 127.094
Long-Term Debt to Total Capital 54.656
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Tandem Diabetes Care Inc - TNDM

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
498.83M 702.80M 801.22M 747.72M
Sales Growth
+37.68% +40.89% +14.00% -6.68%
Cost of Goods Sold (COGS) incl D&A
244.54M 338.23M 400.56M 393.84M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
10.45M 13.85M 14.33M 15.71M
Depreciation
9.25M 11.64M 12.33M 13.81M
Amortization of Intangibles
1.20M 2.20M 2.00M 1.90M
COGS Growth
+40.65% +38.31% +18.43% -1.68%
Gross Income
254.28M 364.57M 400.66M 353.88M
Gross Income Growth
+34.94% +43.37% +9.90% -11.68%
Gross Profit Margin
+50.98% +51.87% +50.01% +47.33%
2020 2021 2022 2023 5-year trend
SG&A Expense
262.24M 341.92M 462.46M 508.36M
Research & Development
54.32M 80.41M 126.78M 155.85M
Other SG&A
207.92M 261.51M 335.68M 352.50M
SGA Growth
+27.82% +30.38% +35.26% +9.92%
Other Operating Expense
- - - -
-
Unusual Expense
17.09M 1.39M 30.89M 78.75M
EBIT after Unusual Expense
(25.04M) 21.27M (92.70M) (233.23M)
Non Operating Income/Expense
1.57M 674.00K 6.06M 22.86M
Non-Operating Interest Income
1.57M 674.00K 6.06M 22.86M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
12.80M 6.04M 6.21M 9.88M
Interest Expense Growth
+16,316.67% -52.83% +2.78% +59.18%
Gross Interest Expense
12.80M 6.04M 6.21M 9.88M
Interest Capitalized
- - - -
-
Pretax Income
(36.28M) 15.90M (92.85M) (220.25M)
Pretax Income Growth
-47.46% +143.83% -683.94% -137.21%
Pretax Margin
-7.27% +2.26% -11.59% -29.46%
Income Tax
(1.90M) 335.00K 1.74M 2.36M
Income Tax - Current - Domestic
75.00K 174.00K 1.44M 653.00K
Income Tax - Current - Foreign
151.00K 161.00K 298.00K 1.70M
Income Tax - Deferred - Domestic
- - - (2.13M)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(34.38M) 15.57M (94.59M) (222.61M)
Minority Interest Expense
- - - -
-
Net Income
(34.38M) 15.57M (94.59M) (222.61M)
Net Income Growth
-38.90% +145.27% -707.70% -135.33%
Net Margin Growth
-6.89% +2.21% -11.81% -29.77%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(34.38M) 15.57M (94.59M) (222.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(34.38M) 15.57M (94.59M) (222.61M)
EPS (Basic)
-0.5637 0.2471 -1.4747 -3.4264
EPS (Basic) Growth
-33.23% +143.84% -696.80% -132.35%
Basic Shares Outstanding
60.99M 63.00M 64.15M 64.97M
EPS (Diluted)
-0.5637 0.2419 -1.4747 -3.4264
EPS (Diluted) Growth
-33.23% +142.91% -709.63% -132.35%
Diluted Shares Outstanding
60.99M 64.35M 64.15M 64.97M
EBITDA
2.49M 36.50M (47.48M) (138.76M)
EBITDA Growth
+123.42% +1,363.43% -230.09% -192.27%
EBITDA Margin
+0.50% +5.19% -5.93% -18.56%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 53.25
Number of Ratings 23 Current Quarters Estimate -0.21
FY Report Date 12 / 2024 Current Year's Estimate -1.693
Last Quarter’s Earnings -0.35 Median PE on CY Estimate N/A
Year Ago Earnings -3.43 Next Fiscal Year Estimate -1.212
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 13 22 22
Mean Estimate -0.21 -0.45 -1.69 -1.21
High Estimates 0.14 -0.19 -1.33 -0.72
Low Estimate -0.37 -0.66 -1.86 -1.51
Coefficient of Variance -55.09 -33.67 -6.47 -16.45

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 12
OVERWEIGHT 3 2 2
HOLD 6 6 5
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Tandem Diabetes Care Inc - TNDM

Date Name Shares Transaction Value
Aug 20, 2024 Brian B. Hansen EVP & Chief Legal Officer 8,754 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 383,600.28
Aug 20, 2024 Rick Carpenter Chief Technology Officer 11,832 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Rick Carpenter Chief Technology Officer 1,787 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Rick Carpenter Chief Technology Officer 11,619 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 509,144.58
Aug 20, 2024 Rick Carpenter Chief Technology Officer 13,056 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Rick Carpenter Chief Technology Officer 12,543 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 549,634.26
Aug 20, 2024 Brian B. Hansen EVP & Chief Legal Officer 10,060 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian B. Hansen EVP & Chief Legal Officer 3,184 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian B. Hansen EVP & Chief Legal Officer 9,678 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 424,089.96
Aug 20, 2024 Brian B. Hansen EVP & Chief Legal Officer 10,191 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 46,368 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian B. Hansen EVP & Chief Legal Officer 8,944 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 38,301 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 6,709 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 2,377 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 49,766 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 2,180,746.12
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 52,540 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 47,068 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 2,062,519.76
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 48,202 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 John F. Sheridan PRESIDENT & CEO; Director 45,966 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.82 per share 2,014,230.12

Tandem Diabetes Care Inc in the News